Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase 2 5Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 255Breast Neoplasms 171Neoplasms 166Colorectal Neoplasms 152Neoplasm Metastasis 125Prostatic Neoplasms 118Recurrence 117Leukemia, Myeloid, Acute 117Melanoma 116Pancreatic Neoplasms 114Ovarian Neoplasms 109Multiple Myeloma 105Lung Neoplasms 94Stomach Neoplasms 92Triple Negative Breast Neoplasms 86Squamous Cell Carcinoma of Head and Neck 86Lymphoma 77Glioblastoma 77Lymphoma, Non-Hodgkin 76Lymphoma, Large B-Cell, Diffuse 65Carcinoma, Renal Cell 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 63Carcinoma, Hepatocellular 58Endometrial Neoplasms 56Advanced Solid Tumor 56Small Cell Lung Carcinoma 55Uterine Cervical Neoplasms 53Sarcoma 53Myelodysplastic Syndromes 51Leukemia 50

Interventions

Eflornithine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neuroectodermal Tumors, Primitive × 1 year × Clear all
NCT06465199 2026-04-13

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡